Pharmaceuticals, Biotechnology & Life Sciences

Teva Pharmaceutical’s dual‑stream strategy drives growth in oncology, nephrology, mTOR and myeloproliferative markets while balancing cost‑control, supply‑chain resilience and value‑based reimbursement for sustained profitability.

Recordati’s recent share dip reflects broader healthcare sector softness, yet the company’s strong R&D pipeline, value‑based reimbursement focus, and cost‑efficient operations keep it poised for long‑term growth.

Shares of Eisai surge 6.4% as Nikkei rebounds, driven by strong biotech pipeline—Aduhelm, Lenvima, Inovelge—and upbeat market expectations for rate cuts.

Explore how Hikma Pharmaceuticals PLC navigates growth in mTOR inhibitors, glycopeptide antibiotics, quinolones and angina drugs while balancing cost‑effective manufacturing, regulatory hurdles and global competition.

Explore the global aesthetic fillers market, its 7.2 % CAGR, leading brands like Galderma, and evidence‑based safety and efficacy insights for clinicians and patients.

How Eli Lilly’s $1T milestone and GLP‑1 drugs Mounjaro & Zepbound are reshaping weight‑loss treatment and driving market growth.

Haleon partners with Altibbi for “Healthy Saudi Smile,” blending science‑based oral‑health education with direct medical access to boost consumer‑health in Saudi Arabia.

AbbVie’s rising earnings outlook, robust oncology pipeline and strategic ADC focus highlight its growth in targeted cancer therapies and long‑term investor confidence.

Positive Asundexian data lifts Bayer shares: 28% stroke risk cut, 23% fewer bleeds, 10% price jump—potential breakthrough anticoagulant for atrial fibrillation.

Merck KGaA secures FDA Fast‑Track for cladribine capsules, a potential oral therapy that could improve muscle strength and daily living for patients with generalized myasthenia gravis.